SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001664710-24-000091
Filing Date
2024-11-06
Accepted
2024-11-06 16:22:16
Documents
56
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q kros-20240930.htm   iXBRL 10-Q 1166659
2 EX-31.1 exhibit311q32024.htm EX-31.1 17235
3 EX-31.2 exhibit312q32024.htm EX-31.2 17116
4 EX-32.1 exhibit321q32024.htm EX-32.1 9852
  Complete submission text file 0001664710-24-000091.txt   4789047

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kros-20240930.xsd EX-101.SCH 32296
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT kros-20240930_cal.xml EX-101.CAL 51240
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT kros-20240930_def.xml EX-101.DEF 146081
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kros-20240930_lab.xml EX-101.LAB 468706
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kros-20240930_pre.xml EX-101.PRE 307173
59 EXTRACTED XBRL INSTANCE DOCUMENT kros-20240930_htm.xml XML 389811
Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Filer) CIK: 0001664710 (see all company filings)

IRS No.: 811173868 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39264 | Film No.: 241431366
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)